Related Experiment Video
Updated: Dec 15, 2025
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
18.6K
Ubrogepant to treat migraine
1Department of Neurology, School of Medicine, University of California, Davis, Sacramento, California, USA. ashishdhirpu@yahoo.com.
Drugs of Today (Barcelona, Spain : 1998)
|July 11, 2020
Summary
Ubrogepant, a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist, effectively treats acute migraine attacks. It offers pain relief and reduces associated symptoms without causing hepatotoxicity.
Area of Science:
- Neurology
- Pharmacology
Background:
- Migraine is a prevalent neurological disorder impacting global populations.
- Calcitonin gene-related peptide (CGRP) plays a crucial role in migraine pathophysiology.
- Elevated CGRP levels are observed during migraine attacks.
Purpose of the Study:
- To review the pharmacology, indication, and safety of ubrogepant for acute migraine treatment.
- To highlight ubrogepant as the first oral CGRP receptor antagonist for migraine.
Main Methods:
- Review of preclinical and clinical data from pivotal phase III trials (ACHIEVE I and ACHIEVE II).
- Analysis of ubrogepant's efficacy, safety, and pharmacokinetic profile.
Main Results:
- Ubrogepant demonstrated effectiveness in treating acute migraine attacks.
- The drug alleviates pain and associated symptoms like nausea and photophobia.
- Ubrogepant showed a favorable safety profile, free from hepatotoxicity at therapeutic doses.
Conclusions:
- Ubrogepant is an effective and safe oral treatment option for acute migraine attacks.
- It provides significant pain relief and symptom management for migraine sufferers.
- Ubrogepant is not indicated for migraine prevention.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
870
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
870
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
352
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
352
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
931
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
931
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
433
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
433
01:26Cholinergic Antagonists: Therapeutic Uses
1.2K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.2K
01:28Angle Closure Glaucoma: Treatment
1.0K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.0K